Search
Big Pharma's Q2 2026 Profits Are In — But Are Patients Still Losing Out on Affordable Medicines?
Big Pharma's Q2 2026 earnings** season, which concluded in early August, showed record profits and raised full-year guidance across most major manufacturers, even as US patient affordability data worsened. This affects patients paying out of pocket in the United States, pharmaceutical companies navigating new pricing regulation, and regulatory affairs professionals working across market access and lifecycle management. It matters now because the Medicare Drug Price Negotiatio
Aug 1413 min read
Twenty Years in Big Pharma — And Still Couldn't Get Into Regulatory Affairs Without Training
Part of the Entry to Regulatory Success Stories Series Forhad had spent over two decades inside three of the most respected organisations in pharmaceutical science — GSK, Charles River Laboratories, and AstraZeneca. He was a Senior Scientist. He had a biochemistry degree and a Master's in Pharmaceutical Sciences. He understood drug molecules from hit identification all the way through to clinical candidate. And when he decided he wanted to move into regulatory affairs, the in
Jun 1914 min read